In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...
Read MoreClinical Trial Posts on Medivizor
Searching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreSearching for patients with advanced non-small cell lung cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...
Read MoreLooking for patients with non-Hodgkin lymphoma to test new treatment using patient’s own immune cells
In a nutshell This trial is examining the effectiveness of CTX110, a treatment that modifies a patient’s own immune cells to treat relapsed or unresponsive non-Hodgkin lymphoma (NHL). The main outcome of this study is to see the number of patients that respond to treatment and side effects experienced. This study is recruiting in...
Read MoreSearching for patients with hormone-sensitive advanced prostate cancer to trial a new treatment
In a nutshell This phase 2 trial will investigate the safety and effectiveness of REGN2810 with androgen deprivation therapy (ADT) and docetaxel (Taxotere) in advanced hormone-sensitive prostate cancer (hsPC). The main outcome will be the percentage of patients with undetectable PSA (prostate-specific antigen; a marker of prostate cancer)...
Read MoreLooking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read MoreLooking for patients with relapsed or unresponsive non-Hodgkin lymphoma to test a new antibody drug
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read MoreLooking for participants with advanced colorectal cancer to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreLooking for participants with metastatic non-small cell lung cancer to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreLooking for participants with metastatic melanoma to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreLooking for patients with type 2 diabetes and high cholesterol to test a cholesterol-reducing drug combination
In a nutshell This trial is examining how effective the drug bempedoic acid is when used with ezetimibe (Zetia) to reduce cholesterol in patients with type 2 diabetes (T2D). The main outcome will be the measurement of patient’s cholesterol as well as heart disease risk, diabetes severity and drug side effects. This study is recruiting in...
Read MoreLooking for participants with benign prostatic hyperplasia and overactive bladder to test a new drug
In a nutshell This phase 3 trial is examining the effectiveness of vibegron in the treatment of overactive bladder symptoms (OAB) in patients with prostatic hyperplasia (BPH; enlarged prostatic gland). The main outcome of this trial will be a change in urgency episodes. This trial is being conducted in the US and Canada. The details A benign (not...
Read More
